News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|May 20, 2024

Contribution of Multiple Pathways to the Development of Alzheimer’s Disease

Sharon Cohen, MD, and Marwan Sabbagh, MD, discuss the current understanding of tau as a marker of neuronal injury and its role in the pathophysiology of Alzheimer's disease, particularly focusing on the significance of phosphorylated tau and neurofibrillary tangles in the disease process.

Episodes in this series

EP. 1 Apolipoprotein E4 in Alzheimer’s Disease

EP. 1 Apolipoprotein E4 in Alzheimer’s Disease

EP. 2 Importance of Early Diagnosis of Alzheimer’s Disease

EP. 2 Importance of Early Diagnosis of Alzheimer’s Disease

Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"

EP. 3 Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease

video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"

EP. 4 Amyloid Cascade Hypothesis of Alzheimer’s Disease

Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"

EP. 5 Contribution of Multiple Pathways to the Development of Alzheimer’s Disease

Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"

EP. 6 Utilization of Neuroimaging in Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 7 CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 8 Utilization of APOE4 Genotype in Management of Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 9 Alzheimer’s Disease Pipeline

A panel of 3 experts on Alzheimer's disease

EP. 10 The Future Outlook for Alzheimer’s Disease

What is the current thinking on multiple mechanisms contributing to different aspects of pathology of Alzheimer’s disease?
- What role does tau, its phosphorylated form, and neurofibrillary tangles of tau protein play in pathophysiology of Alzheimer’s disease?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Annette Langer-Gould, MD, PhD

Rituximab Displays Long-Term Effectiveness for Relapsing MS

ByLouie Pasculli

January 13th 2026

FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease

ByIsabella Ciccone, MPH

January 13th 2026

Samia Ben Sassi, MD

Collaborating Across Global Borders to Improve Understanding of Parkinson Disease: Samia Ben Sassi, MD

BySamia Ben Sassi, MD,Matt Hoffman,Isabella Ciccone, MPH

January 13th 2026

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis

January 13th 2026

Brian Lin, PhD

Enhancing ALS Care Through Genetics, Biomarkers, and Clinical Trial Readiness: Brian Lin, PhD

ByBrian Lin, PhD,Isabella Ciccone, MPH

January 13th 2026

Latest CME

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

In-Person + Virtual Event

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

February 6, 2026

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis

Published Phase 2 Data Highlight Potential of NNZ-2591 in Phelan-McDermid Syndrome

Enhancing ALS Care Through Genetics, Biomarkers, and Clinical Trial Readiness: Brian Lin, PhD

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow